ClinicalTrials.gg
RecruitingNCT07243184HeartEpochUpdated Jul 6, 2026

The Feasibility Study of Polymer Artificial Heart Valve for the Treatment the Mitral Valve Disease.

An interventional study of mitral valve replacement in Severe Mitral Valve Regurgitation, Severe Mitral Valve Stenosis, sponsored by Shanghai HeartEpoch Medical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Shanghai HeartEpoch Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
37th of 40
10 · median 127
Started
2025
with 8 others
No phase
36 of 57
29 open now
Primary completion
2027-11
later than 31 of 45 live
Registered
45th of 57
by date

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 37th largest by planned enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2025, is one of 36 with no phase, reaches primary completion later than 31 of the 45 other live ones, and was the 45th registered.

Mitral Valve Insufficiency

470 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

The study aims to evaluate the feasibility and safety of polymer artificial heart valve designed and developed by Shanghai HeartEpoch Medical technology Co. Ltd. for the treatment of the mitral valve diseases.

03

Conditions studied

  • Severe Mitral Valve Regurgitation, Severe Mitral Valve Stenosis
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 60 years old;
  2. severe mitral regurgitation or severe mitral stenosis confirmed by ECHO;
  3. surgical mitral valve replacement;

Exclusion criteria

Exclusion Criteria:

  1. \< 50%;
  2. History of cardiac surgery or history of cardiac intervention( within 1 year), Concurrent cardiac surgery(excluding tricuspid valve repair surgery or atrial fibrillation ablation) or cardiac interventional procedures;
  3. STS ≥8;
  4. intracardiac mass, thrombus or neoplasm confirmed by echo;
  5. Coronary artery disease that requires revascularization;
  6. A pacemaker need to be implanted;
  7. Severe macrovascular lesions require surgical treatment;
  8. Patients with active bleeding, bleeding tendencies or those who are unable to receive anticoagulant therapy;
  9. There was evidence of acute myocardial infarction within 1 month before the surgery (Q-wave MI or non-Q-wave MI, CK-MB ≥ twice the normal level and/or elevated troponin);
  10. here was a history of cerebrovascular events (CVA) within 1 month before the surgery, including ischemic and hemorrhagic strokes, but excluding (TIA);
  11. Confirmed or suspected diagnosis of infective endocarditis or other active infections;
  12. There are diseases that significantly affect the evaluation of treatment, such as patients with neurological disorders that affect cognitive abilities, and patients with malignant tumors and an expected lifespan of no more than one year;
  13. Other situations in which patients are not suitable to participate in this trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Polymer Artificial Heart Valve

    Device: Polymer Artificial Heart Valve Mitral valve replacement

    Device: mitral valve replacement

Interventions

  • Devicemitral valve replacement

    device: polymer artificial heart valve mitral valve replacement

06

What researchers measure

Primary outcomes

  1. The composite incidence rate of all-cause mortality and reoperation

    Time frame: 3 months

Secondary outcomes

  1. Implantation success rate

    Time frame: after the operation

  2. The change of 6 minutes walk testing(6MWT) from baseline

    Time frame: 3months, 6months

  3. Performance evaluation of implanted valves

    Time frame: 1 day after operation, 7 days after operation, 1 months after operation, 3 months after operation.

  4. The change of NYHA from basement

    Time frame: 7 days after operation, 30 days after operation, 3 months after operation

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 24 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2032
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07243184
Lead sponsor
Shanghai HeartEpoch Medical Technology Co., Ltd
Responsible party
Jiangang Wang (Director of valve and AF surgical center, Beijing Anzhen Hospital) — Principal investigator
First posted
Nov 21, 2025
Start date
Nov 19, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2032 (estimated)
Last update
Jul 6, 2026

Study contacts

Jian Gang Wang
Contact
Jiangangwang@ccmu.edu.cn
+8601064412431

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion